Cargando…

Long Term Results of Radiotherapy in Vulvar Cancer Patients in Slovenia between 1997–2004

BACKGROUND: The aim of this retrospective single institution study was to analyse long term results of vulvar cancer treatment with conventional 2D radiotherapy in Slovenia between years 1997–2004. PATIENTS AND METHODS: Fifty-six patients, median age 74.4 years +/- 9.7 years, mainly stage T2 or T3,...

Descripción completa

Detalles Bibliográficos
Autor principal: Zobec Logar, Helena Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter Open 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765322/
https://www.ncbi.nlm.nih.gov/pubmed/29333124
http://dx.doi.org/10.1515/raon-2017-0024
_version_ 1783292212103086080
author Zobec Logar, Helena Barbara
author_facet Zobec Logar, Helena Barbara
author_sort Zobec Logar, Helena Barbara
collection PubMed
description BACKGROUND: The aim of this retrospective single institution study was to analyse long term results of vulvar cancer treatment with conventional 2D radiotherapy in Slovenia between years 1997–2004. PATIENTS AND METHODS: Fifty-six patients, median age 74.4 years +/- 9.7 years, mainly stage T2 or T3, were included in the study. All patients were treated with radiotherapy, which was combined with surgery (group A), used as the primary treatment (group B) or at the time of relapse (group C). Chemotherapy was added in some patients. Histology, grade, lymph node status, details of surgery, radiation dose to the primary tumour, inguinofemoral and pelvic area as well as local control (LC) and survival were evaluated. RESULTS: Overall survival (OS), disease specific survival (DSS) and LC rates at 10-years for all patients were as follows: 22.7%, 34.5% and 41.1%, respectively. The best 10-years results of the treatment were achieved in the primary operated patients treated with adjuvant radiotherapy +/-chemotherapy (OS 31.9%, DSS 40.6% and LC 47.6%). Positive lymph nodes had a strong influence on LC. In case of positive nodes LC decreased by 60% (p = 0.03) and survival decreased by 50% (p = 0.2). There was a trend to a better LC with higher doses ≥ 54.0 Gy (p = 0.05). CONCLUSIONS: The best treatment option for patients with advanced vulvar cancer is combined treatment with surgery and radiotherapy +/- chemotherapy, if feasible. Radiotherapy with the dose of ≥ 54.0 Gy should be considered to achieve better LC if positive adverse factors are present.
format Online
Article
Text
id pubmed-5765322
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher De Gruyter Open
record_format MEDLINE/PubMed
spelling pubmed-57653222018-01-12 Long Term Results of Radiotherapy in Vulvar Cancer Patients in Slovenia between 1997–2004 Zobec Logar, Helena Barbara Radiol Oncol Research Article BACKGROUND: The aim of this retrospective single institution study was to analyse long term results of vulvar cancer treatment with conventional 2D radiotherapy in Slovenia between years 1997–2004. PATIENTS AND METHODS: Fifty-six patients, median age 74.4 years +/- 9.7 years, mainly stage T2 or T3, were included in the study. All patients were treated with radiotherapy, which was combined with surgery (group A), used as the primary treatment (group B) or at the time of relapse (group C). Chemotherapy was added in some patients. Histology, grade, lymph node status, details of surgery, radiation dose to the primary tumour, inguinofemoral and pelvic area as well as local control (LC) and survival were evaluated. RESULTS: Overall survival (OS), disease specific survival (DSS) and LC rates at 10-years for all patients were as follows: 22.7%, 34.5% and 41.1%, respectively. The best 10-years results of the treatment were achieved in the primary operated patients treated with adjuvant radiotherapy +/-chemotherapy (OS 31.9%, DSS 40.6% and LC 47.6%). Positive lymph nodes had a strong influence on LC. In case of positive nodes LC decreased by 60% (p = 0.03) and survival decreased by 50% (p = 0.2). There was a trend to a better LC with higher doses ≥ 54.0 Gy (p = 0.05). CONCLUSIONS: The best treatment option for patients with advanced vulvar cancer is combined treatment with surgery and radiotherapy +/- chemotherapy, if feasible. Radiotherapy with the dose of ≥ 54.0 Gy should be considered to achieve better LC if positive adverse factors are present. De Gruyter Open 2017-06-16 /pmc/articles/PMC5765322/ /pubmed/29333124 http://dx.doi.org/10.1515/raon-2017-0024 Text en © 2017 Helena Barbara Zobec Logar
spellingShingle Research Article
Zobec Logar, Helena Barbara
Long Term Results of Radiotherapy in Vulvar Cancer Patients in Slovenia between 1997–2004
title Long Term Results of Radiotherapy in Vulvar Cancer Patients in Slovenia between 1997–2004
title_full Long Term Results of Radiotherapy in Vulvar Cancer Patients in Slovenia between 1997–2004
title_fullStr Long Term Results of Radiotherapy in Vulvar Cancer Patients in Slovenia between 1997–2004
title_full_unstemmed Long Term Results of Radiotherapy in Vulvar Cancer Patients in Slovenia between 1997–2004
title_short Long Term Results of Radiotherapy in Vulvar Cancer Patients in Slovenia between 1997–2004
title_sort long term results of radiotherapy in vulvar cancer patients in slovenia between 1997–2004
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765322/
https://www.ncbi.nlm.nih.gov/pubmed/29333124
http://dx.doi.org/10.1515/raon-2017-0024
work_keys_str_mv AT zobeclogarhelenabarbara longtermresultsofradiotherapyinvulvarcancerpatientsinsloveniabetween19972004